The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Advances in extranodal natural killer/T-cell lymphoma
Qing-qing Cai, MD, Sun Yat-Sen University Cancer Center, Guangzhou, China, discusses new strategies in treating extranodal natural killer/T-cell lymphoma (ENKTL). Frequently used treatment regimens include SMILE (etoposide, ifosfamide, methotrexate, and dexamethasone) and AspaMetDex (L-asparaginase, methotrexate and dexamethasone). P-GemOx (pegaspargase, gemcitabine and oxaliplatin) is an alternative regimen that results in comparable patients outcomes to AspaMetDex and has shown to be efficacious and safe in combination with sintilimab in a Phase II clinical trial (NCT04127227). Multiple new drugs such as mitoxantrone and CS1001, an anti-PD-L1 monoclonal antibody, have additionally shown to be effective in patients with relapsed/refractory ENKTL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
